Literature DB >> 1651102

Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells.

R D Woessner1, M R Mattern, C K Mirabelli, R K Johnson, F H Drake.   

Abstract

The cellular content of 170kD and 180kD topoisomerase II was studied as a function of the proliferation state and cell cycle position in NIH-3T3 cells. When the cells were synchronized by serum starvation and then stimulated to enter the cell cycle by addition of fresh growth medium, the amount of 170kD topoisomerase II present was undetectable until the cells reached late S phase, peaked in G2-M phase cells, and decreased as the cells completed mitosis. The amount of 180kD topoisomerase II was constant once the cells entered the cell cycle. When exponentially growing cells were induced to enter G0 by serum starvation, the amount of 170kD topoisomerase II decreased in parallel with the loss of cells from the S and G2-M phases of the cell cycle and was undetectable once all of the cells reached G0. In contrast, the 180kD enzyme was still present after all of the cells had entered G0. The tightness of association of the two enzymes with chromatin was measured by determining the concentration of salt required to extract them from isolated nuclei. The 180kD enzyme required a higher concentration of NaCl for extraction than did the 170kD enzyme. The different patterns of expression of the two forms of topoisomerase II suggest that they perform different functions in cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1651102

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  132 in total

1.  Topoisomerase II-mediated alterations of K562 drug resistant sublines.

Authors:  R Zhou; Y Wang; A Gruber; R Larsson; E Castaños-Vèlez; E Liliemark
Journal:  Med Oncol       Date:  1999-09       Impact factor: 3.064

2.  Sp1 mediates cell proliferation-dependent regulation of rat DNA topoisomerase IIalpha gene promoter.

Authors:  J H Yoon; J K Kim; G B Rha; M Oh; S H Park; R H Seong; S H Hong; S D Park
Journal:  Biochem J       Date:  1999-12-01       Impact factor: 3.857

3.  The topoisomerase IIbeta circular clamp arrests transcription and signals a 26S proteasome pathway.

Authors:  Hai Xiao; Yong Mao; Shyamal D Desai; Nai Zhou; Chun-Yuan Ting; Jaulang Hwang; Leroy F Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-10       Impact factor: 11.205

4.  Cellular distribution of mammalian DNA topoisomerase II is determined by its catalytically dispensable C-terminal domain.

Authors:  N Adachi; M Miyaike; S Kato; R Kanamaru; H Koyama; A Kikuchi
Journal:  Nucleic Acids Res       Date:  1997-08-01       Impact factor: 16.971

5.  Topoisomerase II alpha and II beta expression in childhood acute lymphoblastic leukaemia: relation to prognostic factors and clinical outcome.

Authors:  A J Lodge; A G Hall; M M Reid; G G McIntosh; M Steward; J J Anderson; C H Horne; B Angus
Journal:  J Clin Pathol       Date:  2001-01       Impact factor: 3.411

6.  Influence of cell cycle and oncogene activity upon topoisomerase IIalpha expression and drug toxicity.

Authors:  D W Stacey; M Hitomi; G Chen
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

Review 7.  Topoisomerase II: untangling its contribution at the centromere.

Authors:  Andrew C G Porter; Christine J Farr
Journal:  Chromosome Res       Date:  2004       Impact factor: 5.239

8.  A novel quantitative PCR of proliferation markers (Ki-67, topoisomerase IIalpha, and TPX2): an immunohistochemical correlation, testing, and optimizing for mantle cell lymphoma.

Authors:  Helena Brizova; Marketa Kalinova; Lenka Krskova; Marcela Mrhalova; Roman Kodet
Journal:  Virchows Arch       Date:  2010-04-24       Impact factor: 4.064

9.  Mechanisms of the formation of radiation-induced chromosomal aberrations.

Authors:  Peter E Bryant; Andrew C Riches; Samantha Y A Terry
Journal:  Mutat Res       Date:  2010-03-27       Impact factor: 2.433

10.  The ubiquitin-conjugating enzyme E2-EPF is overexpressed in primary breast cancer and modulates sensitivity to topoisomerase II inhibition.

Authors:  Donato Tedesco; Jianhuan Zhang; Lan Trinh; Guita Lalehzadeh; Rene Meisner; Ken D Yamaguchi; Daniel L Ruderman; Harald Dinter; Deborah A Zajchowski
Journal:  Neoplasia       Date:  2007-07       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.